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ABSTRACT: Oxytocin, a cyclic nine amino acid neurohypophyseal
hormone therapeutic, is eﬀectively used in the control of postpartum
hemorrhaging (PPH) and is on the WHO List of Essential Medicines.
However, oxytocin has limited shelf life stability in aqueous solutions,
particularly at temperatures in excess of 25 °C and injectable aqueous
oxytocin formulations require refrigeration (<8 °C). This is
particularly problematic in the hot climates often found in many
developing countries where daytime temperatures can exceed 40 °C
and where reliable cold-chain storage is not always achievable. The
purpose of this study was to develop N-terminal amine targeted
PEGylation strategies utilizing both linear PEG and polyPEG “comb” polymers as an eﬀective method for stabilizing solution
formulations of this peptide for prolonged storage in the absence of eﬃcient cold-chain storage. The conjugation chemistries
investigated herein include irreversible amine targeted conjugation methods utilizing NHS ester and aldehyde reductive
amination chemistry. Additionally, one reversible conjugation method using a Schiﬀ base approach was explored to allow for the
release of the native peptide, thus, ensuring that biological activity remains unaﬀected. The reversibility of this approach was
investigated for the diﬀerent polymer architectures, alongside a nonpolymer oxytocin analogue to monitor how pH can tune
native peptide release. Elevated temperature degradation studies of the polymer conjugates were evaluated to assess the stability
of the PEGylated analogues in comparison to the native peptide in aqueous formulations to mimic storage conditions in
developing nations and regions where storage under appropriate conditions is challenging.
1. INTRODUCTION
There is an unacceptably large diﬀerence in the death of
mothers during child birth between the developed and
developing world. Maternal mortality in developing regions is
still 14× higher than in the developed regions. The UN lists
reducing the maternal mortality rate to <70 women in every
100000 live births by 2030 as its #1 “Goal 3 Target”.1 Since
1990, worldwide maternal mortality rates have improved;
however, rates are still unacceptably high in developing nations
that will account for 99% of the maternal deaths that occur in
2016. Postpartum hemorrhaging (PPH) is one such complica-
tion, manifesting as excessive and uncontrolled bleeding due to
insuﬃcient contraction of the uterus after delivery. It is
understood that in developing countries, where home births are
common and access to well-resourced health care facilities and
professionals are limited, that obstetric hemorrhage continues
to be a leading cause of maternal deaths and, sadly, a
conservative estimate is that over 140000 women per year die
needlessly of complications arising from PPH.
Oxytocin is a World Health Organization (WHO)
recommended drug currently used across the world as a
uterotonic for the induction of labor and prevention of PPH
and is on the WHO List of Essential Medicines.2−6 PPH is a
worldwide problem, being one of the leading causes of maternal
morbidity, and oxytocin (cyclic [Cys-Tyr-Ile-Gln-Asn-Cys]-
Pro-Leu-Gly-NH2; marketed under trade names Syntocinon
and Pitocin) prevents large amounts of post birth bleeding by
causing the uterus to contract. A signiﬁcant problem with the
use of oxytocin is that it rapidly undergoes degradation in
aqueous solutions, with degradation occurring by a variety of
processes including deamidation, β-elimination, tri/tetrasulﬁde
formation, dimerization, and the formation of larger aggre-
gates.7,8 Oxytocin formulations therefore do not have long shelf
lives and this leads to the requirement of cold-chain supply and
storage, which is not always practical, particularly within the
developing world due to complex economic and social reasons.
Various approaches have been established in attempts to
somewhat resolve this problem with an aim to providing longer
shelf life stability to oxytocin.9−11 There has been a signiﬁcant
amount of research developed since the discovery of oxytocin
into various oxytocin analogues with a focus on analysis of
structural changes and the eﬀect this can have on peptide
activity and stability.12−16 Structurally the amino acids required
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for uterine activity are Tyr2 and Asn5 with Ile3, Gln4, Pro7, and
Leu8 also being important for binding to the receptor.17
Recently, we reported the synthesis of dithiophenol maleimide
functional polyPEGs and conjugated these site-speciﬁcally onto
oxytocin by bridging of the Cys1−Cys6 disulﬁde bond.9 This led
to an increase in the stability of aqueous solutions of the
peptide highlighting the potential of applying PEGylation as a
method for reducing degradation of this therapeutic. Moreover,
previous modiﬁcations at the N-terminal amine where the free
amino group is lacking from the structure of the peptide
(desamino-oxytocin) have shown high levels of uterine
contractility proving potentially more potent than the native
peptide as an oxytocic drug.18−22 A further oxytocin analogue
that has proved fairly successful is carbetocin (1-deamino-1-
monocarba-[2-O-methyltyrosine]-oxytocin), which also has
changes to the amino groups, along with other structural
modiﬁcations. This octapeptide oxytocin alternative has been
approved for human and veterinary use in several countries and
provides eﬀective uterotonic activity while maintaining a higher
stability than the native peptide.23,24 Amino targeting chemistry
is site selective for oxytocin as the only amine group present on
the peptide structure is that at the N-terminus, leading to the
possibility of only one site of polymer attachment. The N-
terminal amine also spatially is very close to the Cys1−Cys6
disulﬁde bond, one of the sites where a large proportion of the
degradation products arise from, and amine targeted con-
jugation strategies, would potentially provide some protection
across this highly susceptible degradation position. Targeting of
the N-terminus in oxytocin could prove advantageous as an
attachment position, as previous studies for diﬀerent oxytocin
analogues where the N-terminus has been functionalized have
still maintained a high amount of oxytocic activity.18,19
The attachment of polymer chains such as poly(ethylene
glycol) (PEG) to peptides and proteins (PEGylation) can oﬀer
a high number of advantages including improved water
solubility, longer blood circulation times, as well as reducing
degradation thus improving shelf life and stability under
stressed conditions.25−30 As a result, there are an increasing
number of FDA approved PEGylated products in the clinic and
many more in clinical studies.31−35 To date, various coupling
chemistries have been evaluated for PEGylation that can react
in a site-speciﬁc manner at diﬀerent amino acids found on
peptide and proteins. Targeted strategies among others have
included the site-selective conjugation at lysine,36−38 cys-
teine,39−43 arginine,44 and tyrosine45 residues.
Unfortunately, many polymer-modiﬁcation procedures result
in a peptide/protein loss of activity following polymer
conjugation.46−48 In order to overcome this problem, a
signiﬁcant amount of research has been conducted into
diﬀerent reversible conjugation approaches, which are able to,
under certain conditions, restore the peptide/protein so that
full function and activity can be maintained.49−58
As an alternative to the conjugation of linear PEG onto
bioactive molecules there have been eﬀorts to incorporate
diﬀerent architectures such as branched “comb” PEGs onto
proteins and peptides.59−65 This can provide a higher density of
PEG and leads to diﬀerences in physical properties which can
oﬀer an alternative to linear equivalents.66 Potential advantages
of comb polymers include possessing a decreased viscosity with
respect to solutions of linear polymers due to being rigid rods
as opposed to random coils in solution and reduced polymer
crystallization and subsequent organ vacuolization.67 The
synthesis of tailor-made polymers bearing low molar mass
PEG side chains by implementing (meth)acrylate PEG
monomers have been more accessible since the development
of living radical polymerization techniques. These are prepared
in a controlled manner by a variety of polymerization
techniques such as atom transfer radical polymerization
(ATRP)68,69 and Cu(0)-mediated living radical polymer-
ization.70−72 A variety of α-end group functionalities can be
incorporated, and the controlled nature of the polymerization
leads to targeted molecular weight (degree of polymerization)
polymers with low dispersities capable of undergoing post
polymerization conjugations onto biological molecules. There
have been several diﬀerent targeting strategies previously
described for the “grafting-to” of polyPEGs onto proteins or
peptides via the incorporation of polymer end group
functionalities. Strategies include the conjugation at thiol
(cysteine) groups using maleimide9,41,73−75 and arsenic76
functional polymers and at amino (lysine or N-terminal)
groups using aldehyde (Schiﬀ base formation/reductive
amination)66,77,78 or N-hydroxysuccinimide (NHS) ester79,80
chemistry.
Herein we describe both linear and polyPEG architectures
for site speciﬁc conjugation onto oxytocin utilizing NHS ester
chemistry for the synthesis of thermally stable conjugates and
aldehyde-amine reactions for the formation of both irreversible
and reversible oxytocin conjugates.
2. MATERIALS AND METHODS
2.1. Materials. Oxytocin (c-[Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-
Gly-NH2) was gifted from PolyPeptide Laboratories (Hillerød,
Denmark) and used as received. Functional poly(ethylene glycol)s:
succinimidyl ester (NHS) functional poly(ethylene glycol) (molecular
weight = 2000 and 5000 Da) and formyl (aldehyde) functional
poly(ethylene glycol) (molecular weight = 2000 and 5000 Da) were
purchased from Rapp Polymere (Germany) and stored in a freezer. All
other chemicals were purchased from Sigma-Aldrich and used without
further puriﬁcation. Copper wire was pretreated by washing in
hydrochloric acid (35%) for 20 min, then rinsed with water, and dried
under nitrogen immediately prior to use. N,N,N′,N′,N″,N″-Hexam-
ethyl-[tris(aminoethyl)amine] (Me6-TREN) was synthesized accord-
ing to a reported procedure and stored at 4 °C.81
2.2. Instruments and Analysis. Nuclear magnetic resonance
(NMR) spectra were acquired on Bruker DPX-300 MHz, HD-300,
and HD-400 spectrometers with samples prepared in deuterated
solvents (CDCl3 or DMSO-d6) and chemical shifts were reported in
parts per million (ppm) with reference to solvent residual peaks. 1D
1H and 2D 1H NMR spectra for unreacted oxytocin and the reaction
products with butyraldehyde were acquired at 298 K on a Bruker
Avance III 600 NMR spectrometer operating at 600.13 MHz for 1H
nuclei using the reaction mixture (2 mM) with 10% D2O for ﬁeld-
frequency lock (further details in SI). Size exclusion chromatography
(SEC) was performed on an Agilent Polymer Laboratories GPC50
ﬁtted with diﬀerential refractive index (RI). Separations were
performed on a pair of Agilent Polargel Medium Columns eluting
with N,N-dimethylformamide containing 0.1 M LiBr as an additive at
50 °C with a ﬂow rate of 1 mL/min. Molecular weights were calculated
relative to narrow poly(methyl methacrylate) (PMMA) standards.
Analytical reverse phase high performance liquid chromatography
(RP-HPLC) was performed on Agilent 1260 inﬁnity series stack
equipped with an Agilent 1260 binary pump and degasser. Samples
were injected using Agilent 1260 autosampler. The HPLC was ﬁtted
with a Phenomenex Lunar C18 column (250 × 4.6 mm) 5 μm packing
(100 Å). Detection was achieved using an Agilent 1260 variable
wavelength detector monitoring at 280 nm. Mobile phases consisted of
acetonitrile and H2O with TFA as an additive (0.04%). Semi-
preparative HPLC was performed on the same HPLC system, using
the same mobile phases as above ﬁtted with a Phenomenex Jupiter C18
column (250 × 21.2 mm) with 5 μm packing (300 Å). Detection was
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achieved using an Agilent 1260 multiple wavelength detector
monitoring at λ = 280 and 225 nm. HPLC gradients are described
in the Supporting Information. MALDI-ToF mass spectrometry was
conducted using a Bruker Daltonics Autoﬂex MALDI-ToF mass
spectrometer. MALDI-ToF samples were made by mixing a saturated
solution of α-cyano-4-hydroxycinnamic acid (CHCA) in methanol as a
matrix (10.8 μL), sodium iodide in tetrahydrofuran (THF; 1.0 mg/
mL) as catonization agent (4.2 μL), and sample in THF with 1 drop of
water (1.0 mg/mL; 10.8 μL) and 0.7 μL of this mixture was applied to
target plate. Spectra were recorded in reﬂector mode calibrating with
methoxy PEG (2000 Da). Electrospray ionization mass spectra (ESI)
were recorded on an Agilent 6130B Single-Quad.
2.3. Methods. N-Hydroxysuccinimide-2-bromo-2-methylpropio-
nate. This procedure was adapted from a previously reported
procedure.79 N-Hydroxy succinimide (4.45 g, 38.7 mmol) was
dissolved in anhydrous DCM (100 mL) and triethylamine (7.16
mL, 51.5 mmol) was added. The ﬂask was cooled to 0 °C before the
addition of α-bromoisobutyryl bromide (5.25 mL, 42.6 mmol) in
DCM (20 mL) dropwise under the ﬂow of nitrogen. The mixture was
stirred at 0 °C for 45 min, before warming to room temperature and
stirring for a further 3 h. The reaction mixture was then poured into
ice−water (200 mL), and the organic layer was separated and washed
with NaHCO3 (2 × 50 mL) followed by water (2 × 50 mL) and again
with NaHCO3 (2 × 50 mL). The organic layer was dried with MgSO4,
and the solvent was removed under reduced pressure. The crude
product was puriﬁed by recrystallization with Et2O to aﬀord N-
hydroxysuccinimide-2-bromo-2-methylpropionate as an oﬀ-white
powder (8.46 g, 32.0 mmol, 83%). 1H NMR (CDCl3, 400.05 MHz)
δ (ppm): 2.06 (6H, s, C(CH3)2Br), 2.85 (4H, s, (CH2CO)2N).
13C
NMR (CDCl3, 100.59 MHz) δ (ppm): 25.54 ((CH2CO)2N), 30.59
(C(CH3)2Br), 51.17 (C(CH3)2Br), 167.40 (NOCO), 168.59
(((CH2CO)2N).
2-(2,2-Dimethoxyethoxy)ethyl-2-bromo-2-methylpropionate.
The two-step protected aldehyde initiator synthesis was adapted from
reported procedure.82 Potassium hydroxide (40 g, 0.71 mol) and
ethylene glycol (100 mL, 1.79 mol) were added together and gradually
heated to 115 °C with stirring. Chloroacetaldehyde dimethyl acetal
was slowly added dropwise, and the solution was stirred for 48 h at
115 °C. The solution was cooled to ambient temperature before the
addition of water (200 mL). The solution was then extracted with
DCM (2 × 150 mL) and washed with brine (2 × 100 mL) before the
organic fractions were dried with MgSO4, and the solvent was
removed under reduced pressure, yielding 2-(2,2-dimethoxy-ethoxy)-
ethanol as a yellow oil (18.1 g, 0.12 mol, 16.9%), which was used for
the subsequent step without further puriﬁcation. 1H NMR (CDCl3,
300.13 MHz) δ (ppm): 3.37 (6H, s, CH(OCH3)2), 3.52 (2H, t, J =
5.09 Hz, CHCH2O), 3.56−3.73 (4H, m, OCH2CH2OH), 4.50 (1H, q,
J = 5.09 Hz, CH(OCH3)2).
13C NMR (CDCl3, 75.47 MHz) δ (ppm):
52.83 (CH(CH3O)2), 61.54 (CH2CH2OH), 70.51 (CH2CH2OH),
72.82 (CHCH2O), 102.47 (CH(CH3O)2).
A solution of 2-(2,2-dimethoxyethoxy)-ethanol (11 g, 73.2 mmol)
and triethylamine (12 mL, 86.2 mmol) were dissolved in DCM (150
mL) and cooled to 0 °C under nitrogen. α-Bromoisobutyryl bromide
(8.5 mL, 69.7 mmol) in DCM (50 mL) was added dropwise. The
solution was stirred for 1 h at 0 °C and overnight at ambient
temperature, and the resulting suspension was ﬁltered. The solution
was then washed with saturated NaHCO3 solution (3 × 100 mL) and
dried with MgSO4, and the solvent was removed under reduced
pressure, yielding a crude yellow oil (18 g). A total of 6.5 g of this oil
was puriﬁed by silica column chromatography (petroleum ether:
diethyl ether; 19:1 to 3:1), yielding 2-(2,2-dimethoxyethoxy)ethyl-2-
bromo-2-methylpropionate as a colorless oil (4.06 g, 12.9 mmol). 1H
NMR (CDCl3, 300.13 MHz) δ (ppm): 1.89 (6H, s, C(CH3)2Br), 3.34
(6H, s, (OCH3)2CH), 3.51 (2H, d, J = 5.09 Hz, CHCH2O), 3.71 (2H,
t, J = 4.71 Hz, OCH2CH2OCO), 4.27 (2H, t, J = 4.71 Hz,
OCH2CH2OCO), 4.45 (1H, t, J = 5.09 Hz, (OCH3)2CH).
13C NMR
(CDCl3, 75.47 MHz) δ (ppm): 30.09 (C(CH3)2Br), 53.31
((CH3O)2CH), 55.00 (C(CH3)2Br), 64.44 (CH2O), 68.41 (CH2O),
70.32 (CH2O), 101.98 ((CH3O)2CH), 170.85 (COC(CH3)2Br).
General Procedure for Cu(0)-Mediated Living Radical Polymer-
ization of mPEGA480. Copper wire (1.25 mm diameter) was activated
by washing in hydrochloric acid for 20 min, before being suﬃciently
rinsed with water and dried under a nitrogen blanket. Cu(II) bromide
(3.7 mg, 0.0167 mmol) was dissolved in DMSO (1.5 mL) in a Schlenk
tube and Me6TREN ligand (16.1 μL, 0.0602 mmol) was added.
Functional initiator (0.334 mmol) in DMSO (1 mL) and mPEGA
(2.94 mL, 6.68 mmol) in DMSO (1 mL) were added. The solution
was degassed with nitrogen bubbling for 20 min prior to the addition
of pre activated copper wire under a positive nitrogen pressure and the
Schlenk tube sealed with a rubber septum. The polymerization was
sampled under a positive pressure of nitrogen for NMR conversion
analysis (DMSO-d6) and SEC molecular weight analysis (DMF).
Polymer Puriﬁcation. The succinimidyl terminated polymers were
puriﬁed by repeated precipitation into diethyl ether/hexane (1:1), and
the protected aldehyde polymers were puriﬁed by dialysis against
water (regenerated cellulose, 1 kDa MWCO, 3 days).
Deprotection of Acetal Group. The acetal groups were removed by
dissolving polymer (1 g) in a (1:1) solution of TFA/H2O (30 mL) and
stirring for 48 h. The aldehyde functional deprotected polymer was
puriﬁed by dialysis against water (regenerated cellulose, 1 kDa
MWCO, 3 days).
PEGylation of Oxytocin with Linear Succinimidyl Polymer.
Oxytocin (20 mg, 19.9 μmol) and NHS-PEG (Rapp-Polymere, 2000
Da; 60 mg, 30 μmol) were separately dissolved in 1 mL of DMF, and
the solutions were added together at 10 °C, along with 20 μL of
triethylamine. After stirring overnight at T = 10 °C, 20 μL of the
solution was removed and dissolved in 1 mL of H2O for RP-HPLC.
PEGylation of Oxytocin with PolyPEG Succinimidyl Polymer.
Oxytocin (1 mg, 0.99 μmol) was dissolved in 1 mL of phosphate buﬀer
(pH 6.5, 0.1 M) and added to succinimide functional polyPEG (65
mg, 10 μmol) dissolved in 1 mL of the same buﬀer. The reaction was
stirred overnight at ambient temperature before a sample was removed
for RP-HPLC analysis.
Example PEGylation of Oxytocin with Linear or “Comb”
Aldehyde PEG. Aldehyde functional PEG (40 mg, 20 μmol) was
dissolved in sodium phosphate buﬀer (5 mL, pH 6.2, 100 mM) and
left at 10 °C for 1 h. Oxytocin (15 mg, 14.9 μmol) was stirred in the
same buﬀer (5 mL) at 10 °C for 15 min. Both solutions were added
together and a freshly prepared solution of NaCNBH3 (25 mmol) was
added. After stirring overnight at T = 10 °C a 100 μL aliquot was taken
and dissolved in 1 mL of H2O for RP-HPLC analysis.
Example Reversible Conjugation of Oxytocin with Butyraldehyde
or Linear or “Comb” Aldehyde PEG. Aldehyde functional linear PEG
(200 mg, 40 μmol) dissolved in phosphate buﬀer (3 mL, pH 8, 0.1 M)
was added to oxytocin (20 mg, 20 μmol) dissolved in the same buﬀer
(2 mL). The reaction was allowed to proceed at room temperature
overnight before a sample was removed for RP-HPLC analysis..
Irreversible Conjugation of Butyraldehyde onto Oxytocin. To
oxytocin (10 mg, 9.9 μmol) in H2O (4 mL), butyraldehyde (4.4 μL,
5.0 μmol) was added after which NaCNBH3 (25 mM, 1 mL) was
added. The reaction was stirred at ambient temperature overnight
before a sample was removed for RP-HPLC.
Reversibility Studies of Butyraldehyde Oxytocin Conjugates.
Butyraldehyde Schiﬀ base conjugated oxytocin solution directly
succeeding conjugation (0.5 mL, 4 mM) was diluted with 1.5 mL of
diﬀerent pH solutions (1 mM). After stirring for 24 h, the samples
were analyzed by RP-HPLC for any increase in concentration of
oxytocin.
Reversibility Studies of Oxytocin−Polymer Conjugates. Immedi-
ately postconjugation to 1 mL of the conjugation solution (4 mM) was
added H2O (3 mL) and the solution dialyzed (3.5 kDa MWCO, 3
day) against water which had been pH adjusted with 0.1 M NaOH to
pH 8. After removal from dialysis a sample was submitted for RP-
HPLC to ascertain minimum oxytocin content. A total of 0.5 mL of
the dialysis solution was diluted with 1.5 mL of solutions at diﬀerent
pHs and stirred for 18 days with periodic sampling by RP-HPLC.
Thermal Stability Assays. Oxytocin and oxytocin−polymer
conjugates (1 μmol unless otherwise stated) were dissolved in
HPLC grade water before being sealed and placed in an oven set at 80
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°C. After 24 h, the samples were removed and allowed to cool to room
temperature before analysis by RP-HPLC (UV: λ = 280 nm). All
solutions were prepared in triplicate and analysis of the remaining
oxytocin (or conjugate) peak was with respect to a 5 point
concentration calibration plot.
3. RESULTS AND DISCUSSION
In this work the syntheses of oxytocin−PEG conjugates are
described using amine reactive succinimidyl ester and Schiﬀ
base/reductive amination aldehyde chemistry comparing linear
and branched architectures in terms of providing potential
stabilization eﬀects. In order to do this, polyPEGs were ﬁrst
synthesized using Cu(0)-mediated living radical polymerization
with targeted molar masses using two diﬀerent initiators for α-
end functionality (Scheme 1), resulting in polymers that have a
“comb” type architecture capable of conjugating onto the N-
terminal amine of oxytocin.
3.1. PolyPEG Synthesis for Post-Polymerization
Conjugations onto Peptides. N-Succinimidyl 2-bromo-2-
methylpropionate was synthesized in one step by reacting N-
hydroxysuccinimide with 2-bromoisobutyryl bromide in a high
yield with little puriﬁcation required.79 An alternative initiator,
which contains a protected aldehyde (acetal) group and has
previously been reported for the controlled synthesis of
poly(mPEGMA) polymers by copper-mediated living radical
polymerization was synthesized in a previously reported two-
step procedure.66,82
The succinimidyl ester initiator was used in the Cu(0)-
mediated living radical polymerization of poly(ethylene glycol)
methyl ether acrylate (avg Mn = 480 g mol
−1, mPEGA480),
which was carried out using anhydrous DMSO as solvent with
Cu(II)Br2, Cu(0) wire, and tris[2-(dimethylamino)ethyl]amine
(Me6TREN) as ligand ([I]/[M]/[Me6TREN]/[CuBr2] =
1:20:0.18:0.05 and 5 cm Cu(0) wire). Samples were removed
periodically and diluted in DMSO-d6 for
1H NMR analysis and
DMF for SEC molecular weight data in order to follow the
kinetics of the reaction. Conversions were measured by
comparing the disappearance of vinyl groups (δ = 5.8−6.4
ppm) against a CH2 signal in the emerging polymer from the
PEG repeat unit (δ = 4.1 ppm). There was an initial inhibition
time to the polymerization, where there was no presence of
polymer by 1H NMR or SEC after 60 min with conversion
rising to 23% after 2 h followed by almost quantitative
conversion (98%) achieved after 24 h (Figure 1A). The
dispersities of the polymers remained low throughout the
reaction (Đ < 1.15), with SEC chromatograms showing
monomodal peaks, and molecular weights increasing through-
out the polymerization (Figure 1B). The linear increase of
molecular weight with conversion (which also correlated well
with theoretical molecular weights) shows evidence of the
controlled nature of this polymerization (Figure 1C,D).
A succinimidyl functional polymer capable of undergoing
conjugation to oxytocin was synthesized targeting a molecular
weight of 6.5 kDa using the same conditions as for the kinetic
experiments but with [M]/[I] ratio =13:1. After 24 h high
conversion was achieved (97%) and the resulting polymer was
puriﬁed by repeated precipitation into Et2O/hexane (1:1) to
yield a succinimidyl ester end functionalized polymer.
Characterization of the puriﬁed polymer by 1H NMR
conﬁrmed that the succinimide group was still present with
Scheme 1. Cu(0)-Mediated Living Radical Polymerization of
mPEGA480 Using Diﬀerent Initiators for α-End
Functionality Capable of Undergoing Post-Polymerization
Peptide Conjugation
Figure 1. Cu(0)-mediated polymerization of mPEGA480 with succinimide ester initiator in DMSO with Me6TREN as ligand showing (A) ﬁnal
conversion by 1H NMR (DMSO-d6, 300.13 MHz), (B) SEC (DMF + 0.1 M LiBr) analysis of polymerization, (C) kinetic plot of molecular weight vs
conversion, and (D) kinetic plot of ln([M]0/[M]n) and conversion vs time.
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the peak at δ = 2.81 ppm representing the four protons in the
succinimide ring. By a comparison between these protons and
the protons from the ﬁrst CH2 of the PEG repeat unit (δ = 4.1
ppm), the average DP was calculated to be 13, yielding an
experimental molecular weight of 6500 g mol−1 with low
dispersity conﬁrmed by SEC (Đ = 1.08; SI, Figure S3).
The Cu(0)-mediated living radical polymerization of
mPEGA480 using the protected aldehyde initiator was carried
out under the same conditions as for the succinimide initiator
([I]/[M]/[Me6TREN]/[CuBr2] = 1:20:0.18:0.05 and 5 cm
Cu(0) wire) for a targeted molar mass of 10 kDa. The
polymerization proceeded at a faster rate compared to that with
the succinimide initiator, with 66% conversion after 2 h and
complete conversion being achieved after 24 h (Figure 2A). As
with the succinimide initiated polymers the molecular weight
distributions remained monomodal and narrow throughout the
polymerization (<1.12), alongside good correlation between
the theoretical and experimental molecular weights (Figure
2B). The kinetics of the reaction revealed controlled character-
istics with a linear evolution of molecular weight (Mn) with
conversion as well as ln([M]0/[M]) increasing linearly with
time (Figure 2C,D).
Two aldehyde functional poly(mPEGA480) polymers were
therefore synthesized for conjugation onto oxytocin using the
acetal-protected aldehyde initiator targeting molecular weights
of 10 and 25 kDa, respectively (equivalent to [M]/[I] of 20 and
50) with [I]/[Me6TREN]/[CuBr2] of 1:0.18:0.05 and 5 cm
Cu(0) wire; overnight).
The α-end group functionality of the puriﬁed (dialysis, 1 kDa
MWCO, 3 days) polymers was conﬁrmed by 1H NMR where
peaks representing the acetal protecting group appear at δ = 4.4
and 3.3 ppm. The experimental molecular weight was
calculated by a comparison between the 6 protons of the
isobutyryl group in the α-end group of the polymer (δ = 1.07
ppm) and the ﬁrst CH2 group of the PEG repeat unit (δ = 4.1
ppm) giving ﬁnal DPs of 21 and 53, representing molecular
weights of 10 kDa and 26 kDa (SI, Figure S4). Furthermore,
SEC analysis (DMF) showed that narrow molecular weight
distributions were maintained, with ﬁnal dispersity values of Đ
= 1.12 and 1.16, respectively.
The polymers were deprotected by addition of aqueous
solutions of triﬂuoroacetic acid (50% v/v), resulting in removal
of the acetal protecting group, thus, yielding α-aldehyde
functionality on the polymer chains. The aldehyde functionality
was conﬁrmed by 1H NMR (DMSO-d6) where there is the
appearance of a characteristic aldehyde peak at 9.5 ppm and a
disappearance of the acetal peaks at 4.4 and 3.3 ppm (SI, Figure
S5). After deprotection of the acetal group, the molecular
weight distribution remained narrow (Đ = 1.15/1.18) and
monomodal, and only a small decrease in average molecular
weight was observed (Table 1 and SI, Figure S6).
3.2. Activated Ester Polymer Conjugation onto
Oxytocin. Succinimide ester (NHS ester) linear PEGs of
two diﬀerent molecular weights (2 and 5 kDa) were conjugated
onto oxytocin in DMF containing 1% TEA to yield amide-
linked linear PEG conjugates (1; Figure 3A). After 18 h, a
sample was taken and submitted for RP-HPLC analysis (UV λ:
280 nm), which showed the appearance of a broad peak at a
higher retention time (t = 14.7 min) with respect to the native
Figure 2. Cu(0)-mediated polymerization of mPEGA480 with acetal-protected initiator in DMSO with Me6TREN as ligand showing (A) ﬁnal
conversion by 1H NMR (DMSO-d6, 300.13 MHz), (B) SEC (DMF + 0.1 M LiBr) analysis of polymerization, (C) kinetic plot of molecular weight vs
conversion, and (D) kinetic plot of ln([M]0/[M]n) and conversion vs time.
Table 1. Summary of the 1H NMR (DMSO-d6) Conversion
and SEC (DMF Eluent) Molecular Weight Data for
Synthesis of NHS Ester and Acetal-Protected/Deprotected
Aldehyde Polymers
polyPEG
conversiona
(%)
Mn
b
(g mol−1) Đb
Mn
b
(g mol−1;
deprotected)
Đb
(deprotected)
6.5 kDa
NHS
97 6500 1.08
10 kDa
NHS
98 11700 1.15
10 kDa
acetal
100 11000 1.12 10500 1.15
25 kDa
acetal
99 21300 1.16 20500 1.18
aDetermined by 1H NMR (DMSO-d6).
bDetermined by SEC (DMF
+ LiBr) using narrow PMMA standards.
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peptide (t = 7.8 min; Figure 3B). The presence of native
oxytocin was observed in the reaction mixture for both
conjugations, indicating that the reaction was not quantitative.
Conjugation was conﬁrmed by MALDI-TOF MS, whereby a
clear shift in molecular weight was observed in the MALDI-
TOF spectrum from the NHS ester polymer to the polymer−
peptide conjugate (Figure 3C). After conjugation (with
puriﬁcation by semipreparative RP-HPLC) there is only one
major peak distribution present with good agreement between
the exact masses achieved from the spectra and the theoretical
(calculated) values and distances between peaks representative
of the ethylene glycol repeat unit (44.03 Da), thus, validating
the expected conjugate structure (Figure 3D).
Conjugation of oxytocin with the 6.5 kDa α-succinimide
polyPEG “comb” was then attempted, which would give a
conjugate with equivalent amide linkage between the peptide
and the polymer, but with a diﬀerent PEG architecture (Figure
3E). However, under the same conditions as the linear
Figure 3. (A) Structure of linear succinimydyl PEG−oxytocin conjugate (1), (B) analysis by RP-HPLC, (C) MALDI-TOF MS of shift in molecular
weight from polymer to polymer conjugate and (D) MALDI-TOF MS of polymer conjugate (1), (E) Structure of “comb” succinimidyl polyPEG−
oxytocin conjugate (2), (F) analysis by RP-HPLC.
Figure 4. (A) Structure of linear aldehyde PEG−oxytocin conjugate (3), (B) analysis by RP-HPLC, (C) MALDI-TOF MS of shift in molecular
weight from polymer to polymer conjugate and (D) MALDI-TOF MS of polymer conjugate (3), (E) Structure of “comb” aldehyde functional
polyPEG−oxytocin conjugate (4), (F) analysis by RP-HPLC.
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analogues ([oxytocin]/[polymer] = 1:1.2), no conjugation was
observed by RP-HPLC within 24 h. The reaction was then
performed using a higher excess of the polymer (10 equiv).
After 24 h, analysis by RP-HPLC (UV λ= 280 nm) showed the
appearance of a broad peak at a higher retention time (t = 23.7
min) compared to the native peptide (t = 12.0 min) attributed
to the polyPEG conjugate (2; Figure 3F). The requirement for
a high excess of polymer is likely due to a combination of the
rapid hydrolysis of the succinimide end group causing the
polymer to no longer have an activated ester end functionality
and issues arising from the steric nature of the polyPEG
chains.83 From the RP-HPLC as observed for the linear
PEGylation with succinimidyl functional polymer there is still
some native oxytocin present after conjugation (t = 12.2 min),
which was easily removed during puriﬁcation by dialysis.
3.3. Aldehyde Functional Polymer Conjugation onto
Oxytocin. Typically when aldehyde chemistry is employed to
modify the amines in proteins and peptides a two-step process
is employed, the ﬁrst involving the reversible formation of a
Schiﬀ base intermediate. Then the irreversible product (a
secondary amine linked peptide−polymer conjugate) is
generated via reductive amination by the subsequent addition
of a reducing agent such as sodium cyanoborohydride
(NaCNBH3).
The irreversibly linked linear aldehyde-PEG conjugation to
oxytocin was carried out in phosphate buﬀer (0.1 M, pH 6.2)
with the addition of NaCNBH3 (25 mM) at two diﬀerent
molecular weights (2 kDa and 5 kDa; 3; Figure 4A). After 24 h,
a sample was submitted for RP-HPLC analysis which conﬁrmed
the formation of a new product, with a new broad peak being
observed with a longer retention time (t = 14.0 min) than the
native peptide (t = 7.4 min), conﬁrming the presence of the
linear PEG−oxytocin conjugate (Figure 4B). Any remaining
native peptide was removed during puriﬁcation of the polymer
conjugate by dialysis (1 kDa MWCO, 3 days), after which the
PEGylated oxytocin product was conﬁrmed by MALDI-TOF
MS. There is a clear shift on the MALDI spectra between the
aldehyde polymer and the polymer conjugate relating to the
MW of oxytocin (Figure 4C). The MALDI spectrum for the
polymer conjugate showed only one major distribution with
experimental masses close to theoretical (calculated) values and
diﬀerences between peaks corresponding to the ethylene glycol
repeat unit (44.03 Da; Figure 4D).
The conjugation of an aldehyde functional polyPEG onto
oxytocin was carried out in the same manner as the conjugation
of linear aldehyde PEG, resulting in an amine-linked “comb”
polymer conjugate (4; Figure 4E). RP-HPLC analysis revealed
the appearance of a substantial broad peak, at a higher retention
time (t = 20.6 min) than for oxytocin (t = 7.1 min), signifying
the synthesis of a newly formed peptide−polymer conjugate
(Figure 4F). There was a variety of smaller baseline peaks that
were also observed on the HPLC trace, although a sample of
the puriﬁed polymer reagent revealed peaks at identical
retention times, suggesting minor impurities in the polymer
solution. Although it is likely that the puriﬁed conjugates still
contained some residual unconjugated polymers (in the case of
both linear and polyPEG), when these reagents were separately
analyzed by RP-HPLC (UV, λ = 280 nm) no obvious peaks
were observed in similar regions to those realized after
conjugation. This suggests that the broad conjugate peaks in
all cases were attributable to peptide−polymer conjugates.
3.4. Use of Aldehyde Functional Polymers for
Reversible PEGylation of Oxytocin. As the ﬁrst step of
the aldehyde conjugation is a reversible reaction, it was
proposed that this linkage could be used to form reversible
oxytocin conjugates, whereby the polymer could be removed by
an external stimulus (such as a change in pH), allowing the
therapeutic to maintain complete activity. The reversible
conjugation of linear PEG onto oxytocin was performed in
phosphate buﬀer (0.1 M, pH 6.2) with the exclusion of the
reducing agent forming the Schiﬀ base product (5; Figure 5A).
After 24 h, a sample was submitted for RP-HPLC analysis, and
for both molecular weights of PEG (2 and 5 kDa), the RP-
HPLC chromatograms showed the appearance of a bimodal
Figure 5. Formation of potentially reversible peptide−polymer conjugates: (A) structure and (B) RP-HPLC trace for formation of linear oxytocin
conjugate (5); (C) structure and (D) RP-HPLC trace for formation of “comb” polymer oxytocin conjugate (6); and (E) structure and (F) RP-
HPLC trace for formation of butyraldehyde oxytocin conjugate.
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peak at a higher retention time (t = 14.8 and 15.6 min) than for
oxytocin (t = 7.3 min; Figure 5B). The reaction was
subsequently performed at a higher pH (pH 8.0) to investigate
the formation of these two products under mildly basic
conditions, potentially minimizing acid hydrolysis. However,
even at higher pH, the presence of a bimodal product peak was
further observed, suggesting that two distinct conjugate
products were being formed at both pHs. The ratio between
the peaks was approximately equivalent for both the mildly
acidic and mildly basic pHs, although it was noted that
following longer reaction monitoring, the second peak started
to become more prominent, regardless of the pH used in the
conjugation process. An investigation of the speed of the
reaction showed that there was a higher formation of both
conjugate products with respect to oxytocin at pH 8, with a
smaller proportion of the native peptide remaining (SI, Figure
S7). It was proposed that these two peaks could represent the
diﬀerent imine stereo isomers (E/Z) that can be formed during
Schiﬀ base formation.
In a similar manner the aldehyde functional polyPEG (10
kDa) was conjugated onto oxytocin without the aid of a
reducing agent, leading to the formation of a Schiﬀ base linked
“comb” polymer conjugate (6; Figure 5C). This conjugation
was carried out in phosphate buﬀer (0.1 M. pH 8), and
sampling by RP-HPLC after 24 h revealed the presence of a
newly formed single broad peak at a higher retention time (t =
24.1 min) than for the native peptide (t = 12 min; Figure 5D).
In order to more thoroughly analyze the formation of the
two diﬀerent products formed in the reversible reaction
between oxytocin and aldehyde functional linear PEG, a
model reaction was examined using butyraldehyde as a
comparable water-soluble small aldehyde (Figure 5E). The
reaction was performed in phosphate buﬀer (0.1 M, pH 8) with
a sample removed for RP-HPLC analysis of the reaction
mixture after 24 h. This showed the formation of two distinct
peaks; butyraldehyde conjugate peak 1 (BCP1) at t = 15.9 min
and butyraldehyde conjugate peak 2 (BCP2) at 16.5 min, both
at higher retention times than for the native peptide (t = 11.7
min; Figure 5F). These distinct peaks were more resolved than
those products observed for the linear PEGylated products,
with peak shape and peak intensity being much more
comparable to the native peptide. It was also noted that
when the conjugation of butyraldehyde and the polymers onto
oxytocin were compared, only residual amounts of native
peptide remained after 24 h in the butyraldehyde conjugation,
suggesting that this reaction was more eﬃcient. The two
butyraldehyde conjugate products, BCP1 and BCP2 were then
separated and individually collected using RP-HPLC and
analyzed by ESI-MS for diﬀerences in molecular weight. The
major product observed in both cases was the oxytocin−
butyraldehyde product [M + H+] = 1061.4 Da, although some
native peptide was also observed as a minor component [M +
H+] = 1007.3 Da. Some Schiﬀ base hydrolysis occurred due to
the low pH (∼2.1) of the resting solutions from RP-HPLC as a
result of the TFA additive, particularly after a prolonged
exposure. This is particularly notable for BCP1, where after
long storage times, only residual conjugate is remaining;
although BCP2 also shows a high decrease in concentration of
the conjugate, the only major product observed in both cases
was conﬁrmed as regenerated oxytocin by RP-HPLC and ESI-
MS (SI, Figure S8).
In order to conﬁrm that this appearance of more than one
product/isomer is a particular characteristic of the reversible
conjugation, the conjugation of butyraldehyde was also carried
out with the addition of NaCNBH3 leading to the irreversibly
linked secondary amine conjugate. As with the two aldehyde
PEGylations with addition of reducing agent NaCNBH3, RP-
HPLC analysis showed the formation of a single peak at a
higher retention time (t = 13.6 min) than for oxytocin (t = 12.1
min) accompanied by an almost complete disappearance of the
peak corresponding to the native peptide (SI, Figure S9). The
irreversibly formed butyraldehyde conjugate was conﬁrmed by
ESI-MS, where the only major peak observed was relatable to
the predicted product [M + Na+] = 1085.3 Da.
In a separate study, one experiment was performed with “in
situ” reduction (as with standard procedure), while the other
was performed with sequential Schiﬀ base formation and
reduction. In the sequential experiment, the distinct isomers
converged to a signal peak upon reduction, identical to that
obtained from the “in situ” reduction experiment (SI, Figure
S10).
NMR analysis was conducted on the butyraldehyde
conjugate reaction mixture (without addition of NaCNBH3)
and compared to that of the native peptide (SI, Figure S11).
This showed that for the Schiﬀ base conjugate there was the
presence of two new doublet peaks within the imine region of
the spectra could be observed (7.84/7.56 ppm), likely due to
Schiﬀ base formation. The two imine proton signals showed
TOCSY connectives of two diﬀerent signals, both assignable to
the α proton of the Cys1 residue. Additionally, the peaks
representing the aromatic groups on the tyrosine residues show
a chemical shift postconjugation (native peptide: δH = 7.16, εH
= 6.83 ppm; butyraldehyde: δH = 7.09, εH = 6.85 ppm), where
Tyr2 is the next amino acid from the N-terminal amine within
the peptide structure. The reaction mixtures also included
excess aldehyde, for which peaks are still visible for the
unreacted aldehyde as well as the hydrate formed during the
hydrolysis of the aldehyde after the addition of water where the
peaks at δ = 5.00 ppm are particularly prominent. These results
conﬁrm that the conjugation has occurred in the predicted
manner, and the appearance of two diﬀerent imine peaks assists
in clarifying that there are two stereoisomers formed.
3.5. Reversibility Studies of Schiﬀ Base Linked
Oxytocin Conjugates. The reversibility of the Schiﬀ base
linked (reversible) conjugates (linear PEGylated oxytocin,
polyPEGylated oxytocin, and butyraldehyde conjugated oxy-
tocin) were studied using RP-HPLC to highlight changes in
concentrations of the peptide or the conjugates. The studies
were performed under diﬀerent pH conditions to investigate
the stability of the linkages and the practicability of recovering a
product analogous to the native peptide, with an element of
control over pH stimulation. Under these pH stimulated
conditions, the native peptide itself remains stable for the time
scale of the experiment, meaning that the released oxytocin
should have retained the properties of the native peptide prior
to conjugation (SI, Figure S12).
For the butyraldehyde−oxytocin conjugate, this reversibility
experiment was carried out immediately post-conjugation due
to the high eﬃciency of the reaction that resulted in minimal
remaining oxytocin. A sample of the conjugation solution was
diluted with two buﬀers, one at pH 5.0 (citrate buﬀer, 0.1 M)
and the other pH 7.4 (phosphate buﬀer, 0.1 M), to give overall
concentrations of 0.2 mg/mL of peptide. After 4 days, the pH
5.0 solution showed a high (10-fold) increase in the amount of
oxytocin present in the solution (from 68.2 to 682 mAUs),
which also corresponded to a decrease in the peak area for both
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of the conjugate peaks (BCP1 and BCP2; Figure 6A,B).
Analysis of the two conjugate peaks revealed that BCP2
showed a much smaller decrease in area, signifying that there
was not a large change in concentration for this isomer (BCP1,
49% decrease; BCP2, 3% decrease; overall, 30% decrease; SI,
Figure S13). For the pH 7.4 buﬀer, a moderate (3-fold)
increase in the amount of oxytocin present in solution could
still be observed (68.2−199 mAUs), but there was not a high
accompanying decrease in the area of the combined conjugate
peaks (BCP1 + BCP2: 8% decrease). That said, the relative
ratios of BCP1 and BCP2, with a decrease in BCP1 and an
increase in BCP2 respectively, suggest that BCP2 is the more
stable conjugate product (0.58:0.42 to 0.45:0.55).
This diﬀerence between the two pHs observed in these data
clearly shows that the reversal of the conjugation can be
somewhat controlled by using pH as a means to induce release
of native peptide. For further investigation, the reversible nature
of the Schiﬀ base linked PEGylated oxytocin (both linear and
polyPEG) was analyzed for oxytocin release and conjugate
disappearance at diﬀerent pHs. For both the polyPEG and
linear PEG conjugates, two pH conditions were again
examined: pH 5.0 and 7.4. The appearance of oxytocin was
monitored to investigate whether it was possible to stimulate a
higher release of the native peptide under a particular pH, as
observed with the nonpolymer analogue.
For the linear PEGylated conjugate, the oxytocin release was
monitored by RP-HPLC after storage in the diﬀerent pH
solutions for a 3 week period. The RP-HPLC traces show the
appearance of oxytocin at both pHs when compared to t = 0
samples (Figure 6C). After 2 weeks the amount of oxytocin
released at pH 5.0 showed a 12-fold increase, approximately
double that released at pH 7.4 (t = 0:25 mAUs, pH 5:302
mAUs; pH 7.4:168 mAUs; Figure 6D). The disappearance of
conjugates was also monitored, with similar behavior to the
butyraldehyde conjugate being observed whereby the ﬁrst
conjugate peak is much more prone to hydrolysis releasing the
native peptide. This was evaluated at both pH values but is
particularly prominent under more acidic conditions (60%
decrease at pH 5.0; 38% decrease at pH 7.4; SI, Figure S13).
The release was further monitored at several diﬀerent time
points, and it revealed that the initial level of oxytocin released
was approximately the same at both pH 5 and 7.4, but at pH 7.4
this starts to plateau in the observed amount of oxytocin
released after 4−6 days (SI, Figure S14). The oxytocin
concentration, however, continued to gradually increase for
the pH 5 solution across the study, showing potential for a
sustained release of oxytocin from the conjugates over time.
For the polyPEG conjugates, there was no appreciable
reversal of the peptide conjugation or release of the native
peptide observed by the end of the study. From the RP-HPLC
there was very little change to the peptide region of the
chromatogram for the reappearance of native oxytocin and
minimal concentration changes to the single broad conjugate
peak, regardless of pH. This suggests that the reverse reaction
was not occurring to release the native peptide over the same
time scale. It can therefore be hypothesized that the structural
design of the conjugates plays an important role in the ability to
reverse the conjugation under stimulated conditions, with larger
and more branched polymers proving less prone to reversion.
3.6. Eﬀect of PEG Architecture on Peptide Stabiliza-
tion. In order to determine the extent of improved shelf life
stability for the irreversibly linked oxytocin conjugates at high
temperature (80 °C), a heat stressed stability assay was devised.
The high temperature was needed in order to give an
appreciable degradation of oxytocin, so that reliable stability
comparisons could be achieved over a reasonable time frame.
The thermal stability was tested for the native peptide, each
type of oxytocin conjugate linkage (linear and polyPEG both by
succinimide and Schiﬀ base/reductive amination conjugation)
as well as solutions containing oxytocin with similar (non-
conjugated) PEGs added as excipients into the solution (SI,
Table S1). All samples were tested in triplicate, with the
concentrations of remaining substances being calculated from
peak areas using UV (λ = 280 nm) absorbance of the peaks on
RP-HPLC examined with respect to calibrations performed on
nondegraded samples (Figure 7).
Under the conditions of this heat stability assay oxytocin (1
mM) showed a high level of degradation after 24 h, with a very
low oxytocin recovery (19.2 ± 1.10%), which is consistent with
Figure 6. (A) RP-HPLC traces and (B) increase in oxytocin observed for reversal of oxytocin−butyraldehyde conjugates at pH 5.0 and pH 7.4, (C)
RP-HPLC traces, and (D) increase in oxytocin observed for reversal of oxytocin−linear PEG conjugates at pH 5.0 and pH 7.4.
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similar high temperature heat stressed assays which have been
carried out previously for oxytocin.8,84 A comparison of the
HPLC traces before and after the stability assay shows the
appearance of numerous degradation products, which supports
previous research on the diﬀerent manners that the peptide
undergoes degradation.7,8,85 Next the eﬀect of nonconjugated
PEGs of both diﬀerent architectures (linear and polyPEG) were
evaluated whereby polymers with similar molar mass but no
conjugating groups were used to evaluate the inﬂuence of
noncovalent polymer−peptide interactions. Upon addition of
linear methoxy PEG (5 kDa) as a 1:1 mixture with the peptide,
the degradation of oxytocin was still very high, with the
polymer proving ineﬃcient at providing any additional
stabilization (oxytocin recovery: 17.7 ± 2.78%). Poly-
(mPEGA480) was synthesized by Cu(0)-mediated living radical
polymerization, using ethyl α-bromoisobutyrate (EBIB) as the
initiator targeting a DP of 20 (94% conversion, Mn = 12300 g
mol−1, Đ = 1.06), which could be used in the same manner as a
polyPEG excipient in the oxytocin solution. A 1:1 mixture of
the poly(mPEGA480) and oxytocin in water showed marginal
improvement in the recovery of oxytocin (33.1 ± 0.21%),
highlighting that the polyPEGs possibly have potentially better
protection properties on the peptide. As the polyPEG sample
was synthesized as 20 repeat units of a smaller linear mPEGA
monomer, the stability study was repeated using a ratio of 20:1
of a small linear methoxy PEG (350 Da) to oxytocin. For this
higher ratio of small PEG chains, no further stabilizing eﬀect
was observed for the peptide with oxytocin recovery remaining
low (19.0 ± 0.56%).
The conjugation of polyPEG onto oxytocin at the disulﬁde
bond has previously been shown to dramatically enhance the
stability of the peptide, and therefore it was anticipated that the
N-terminally conjugated polymers would also exhibit improved
stability.9 When the irreversibly conjugated oxytocin conjugates
underwent the high temperature thermal stability assay the
results suggested that this was the case with high increases in
conjugate recovery compared to the native peptide. The
degradation was measured by comparing the broad conjugate
peak observed on RP-HPLC at t = 0 and 24 h, to calculate any
change in concentrations, and all reductions attributed to
degradation of the conjugates. For all four diﬀerent conjugates
(linear PEG and polyPEG linked by aldehyde/reductive
amination as well as succinimide chemistry) stabilities were
seen to increase leading to oxytocin-conjugate recovery of over
70% for all samples. The comb polymer architecture is
particularly noteworthy, as degradation remained very low
with oxytocin-conjugate recoveries remaining around 100%.
These results prove very promising in showing that the
conjugation of PEG onto oxytocin via the N-terminal amine
can prove beneﬁcial for reducing degradation and extending
shelf life stability at high temperatures.
4. CONCLUSION
Diﬀerent methods of conjugating linear PEG and polyPEG site
speciﬁcally to the N-terminal amine of the peptide therapeutic
oxytocin have been explored, with an aim of improving the
shelf life stability of the aqueous formulations of the drug. This
has the potential for extending the application of this WHO
essential medicine to help address maternal mortality in the
developing world. Well-deﬁned “comb” polymer synthesis was
achieved utilizing copper-mediated living radical polymer-
ization, and alongside linear polymer equivalents, conjugation
strategies have incorporated well-developed succinimide and
Schiﬀ base/reductive amination couplings. The reversible
conjugation of linear PEG aldehydes to the N-terminal amine
suggests potential methods for use of these types of
conjugations as a release mechanism, recovering the active
form of the peptide. Upon conjugation two diﬀerent isomers
(E/Z) can be formed, each exhibiting diﬀerent reversibility
characteristics and the reversibility of the conjugation was
found to be tunable by externally changing the pH, leading to
high releases of native peptide, particularly at lower pH. In
contrast, the polyPEG Schiﬀ base conjugates did not release
oxytocin signiﬁcantly over the time frame of our experiments.
In general, the conjugation of the polymers led to dramatic
increases in stability of the peptide under high temperature
conditions, resulting in a reduction of inactive degradation
products of the peptide. Following on from this work, it is
important to note that the uterotonic activity of the irreversible
polymer conjugates will be investigated. These will be
compared to the reversible conjugates at diﬀerent stages of
oxytocin return, as well as the native peptide, for an evaluation
of any potential losses of activity post-conjugation.
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Jevsěvar, S.; Godwin, A.; Williams, P. Bioconjugate Chem. 2015, 26,
452.
(67) Bendele, A.; Seely, J.; Richey, C.; Sennello, G.; Shopp, G.
Toxicol. Sci. 1998, 42, 152.
Biomacromolecules Article
DOI: 10.1021/acs.biomac.6b00919
Biomacromolecules 2016, 17, 2755−2766
2765
(68) Kamigaito, M.; Ando, T.; Sawamoto, M. Metal-catalyzed living
radical polymerization. Chem. Rev. 2001, 101, 3689.
(69) Matyjaszewski, K.; Xia, J. Chem. Rev. 2001, 101, 2921.
(70) Rosen, B. M.; Percec, V. Chem. Rev. 2009, 109, 5069.
(71) Percec, V.; Guliashvili, T.; Ladislaw, J. S.; Wistrand, A.;
Stjerndahl, A.; Sienkowska, M. J.; Monteiro, M. J.; Sahoo, S. J. Am.
Chem. Soc. 2006, 128, 14156.
(72) Simula, A.; Nikolaou, V.; Alsubaie, F.; Anastasaki, A.;
Haddleton, D. M. Polym. Chem. 2015, 6, 5940.
(73) Mantovani, G.; Lecolley, F.; Tao, L.; Haddleton, D. M.; Clerx, J.;
Cornelissen, J. J. L. M.; Velonia, K. J. Am. Chem. Soc. 2005, 127, 2966.
(74) Bays, E.; Tao, L.; Chang, C. W.; Maynard, H. D.
Biomacromolecules 2009, 10, 1777.
(75) Robin, M. P.; Wilson, P.; Mabire, A. B.; Kiviaho, J. K.; Raymond,
J. E.; Haddleton, D. M.; O’Reilly, R. K. J. Am. Chem. Soc. 2013, 135,
2875.
(76) Wilson, P.; Anastasaki, A.; Owen, M. R.; Kempe, K.; Haddleton,
D. M.; Mann, S. K.; Johnston, A. P. R.; Quinn, J. F.; Whittaker, M. R.;
Hogg, P. J.; Davis, T. P. J. Am. Chem. Soc. 2015, 137, 4215.
(77) Sayers, C. T.; Mantovani, G.; Ryan, S. M.; Randev, R. K.; Keiper,
O.; Leszczyszyn, O. I.; Blindauer, C.; Brayden, D. J.; Haddleton, D. M.
Soft Matter 2009, 5, 3038.
(78) Ryan, S. M.; Wang, X.; Mantovani, G.; Sayers, C. T.; Haddleton,
D. M.; Brayden, D. J. J. Controlled Release 2009, 135, 51.
(79) Lecolley, F.; Tao, L.; Mantovani, G.; Durkin, I.; Lautru, S.;
Haddleton, D. M. Chem. Commun. 2004, 2026.
(80) Nicolas, J.; Khoshdel, E.; Haddleton, D. M. Chem. Commun.
2007, 1722.
(81) Ciampolini, M.; Nardi, N. Inorg. Chem. 1966, 5, 41.
(82) Tao, L.; Mantovani, G.; Lecolley, F.; Haddleton, D. M. J. Am.
Chem. Soc. 2004, 126, 13220.
(83) Nauka, P. C.; Lee, J.; Maynard, H. D. Polym. Chem. 2016, 7,
2352.
(84) Poole, R.; Piotr, T. K.; Jiskoot, W. J. Pharm. Sci. 2011, 100, 3018.
(85) Gard, J. W.; Alexander, J. M.; Bawdon, R. E.; Albrecht, J. T. Am.
J. Obstet. Gynecol. 2002, 186, 496.
Biomacromolecules Article
DOI: 10.1021/acs.biomac.6b00919
Biomacromolecules 2016, 17, 2755−2766
2766
